Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aprea Therapeutics Inc (NQ: APRE )

5.170 -0.200 (-3.72%)
Streaming Delayed Price Updated: 3:15 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aprea Therapeutics Inc

< Previous 1 2 Next >
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Inc. (NASDAQ: APRE) Making Surprising Moves in Thursday Session
Via Investor Brand Network
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
Four Poster Presentations, Including Posters on ATRN-119 (novel macrocyclic ATR inhibitor) and APR-1051 (next generation WEE1 kinase inhibitor) 
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways
Event featuring Fiona Simpkins, M.D. and Timothy A. Yap, MBBS, PhD, FRCP to take place on October 31, 2023 at 11:00 am ET 
From Aprea Therapeutics
Via GlobeNewswire
Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics to Present at BIO International Convention
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual Meeting
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics to Present at Oppenheimer’s 33rd Annual Healthcare Conference
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common Stock
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces Proposed Public Offering of Common Stock
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces Phase II SBIR Award from the National Cancer Institute (NCI)
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Appoints John Hamill as Chief Financial Officer
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics to Participate in 6th Annual DNA Damage and Response (DDR) Inhibitors Summit
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors
From Aprea Therapeutics
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.